Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

CLL State of the Art Update: Ibrutinib Prolongs PFS Compared to CIT, Combinations Achieve uMRD, Venetoclax Obinutuzumab is Highly Effective, & Next Generation BTKi's Are Better Tolerated

316 views
October 18, 2019
0 Comments
Login to view comments. Click here to Login
Chronic Lymphocytic Leukemia